Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer

Currently, patients with radioiodine refractory differentiated thyroid cancer (RAIR-DTC) have limited treatment options. In this study, we aimed to assess the short-term efficacy and safety of apatinib in RAIR-DTC. Ten adult patients were prospectively enrolled to receive oral apatinib (750 mg q.d)....

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yansong, Wang, Chen, Gao, Wen, Cui, Ruixue, Liang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522064/
https://www.ncbi.nlm.nih.gov/pubmed/28178685
http://dx.doi.org/10.18632/oncotarget.15036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522064/
https://www.ncbi.nlm.nih.gov/pubmed/28178685
http://dx.doi.org/10.18632/oncotarget.15036

Ejemplares similares